Craif raises $33M Series D for urine-based AI cancer test

Aug 18, 2026 · Issue 3 · 2 sources, 2 articles

Craif has raised $33M to bring its AI-powered urine-based cancer test to the U.S.

Who is affected and how

medtech company

A new player in urine-based AI cancer screening has appeared on the U.S. market.

Sources

• Craif Raises $33M Series D to Bring Urine-Based AI Cancer Test to the U.S. - MedPath Trialtrial.medpath.com · Aug 18, 2026
• Craif’s $33M Series D funds AI urine test for pancreatic cancer – Medsparkmedspark.ai · Aug 19, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.